Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer: SOLO2 Phase III

被引：0
|
作者：
Hasenburg, A. [1 ]
Harter, P. [2 ]
Park-Simon, T-W. [3 ]
Gropp-Meier, M. [4 ]
Heitz, F. [2 ]
Soergel, P. [5 ]
Ataseven, B. [6 ]
Friedlaender, M. [7 ]
Hilpert, F. [8 ]
Pujade-Lauraine, E. [9 ]
机构：
[1] Univ Ctr Mainz, Dept Gynecol & Obstet, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany
[2] Kliniken Essen Mitte, Gynakol & Gyn Onkol, Essen, Germany
[3] Hannover Med Sch, Klin Frauenheilkunde & Geburtshilfe, Hannover, Germany
[4] Malteserkrankenhaus Bonn, Ravensburg, Germany
[5] Hannover Med Sch, Hannover, Germany
[6] Kliniken Essen Mitte, Klin Senol, Essen, Germany
[7] Prince Wales Hosp, Randwick, NSW, Australia
[8] Univ Klinikum Schleswig Holstein, Klin Gynakol & Geburtshilfe, Kiel, Germany
[9] Univ Paris 05, Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
538
引用
收藏
页码：88 / 89
页数：2
相关论文
共 48 条
  • [41] Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC): Exploratory biomarker analyses of the phase IIIb OPINION study
    Lindemann, K.
    Skof, E.
    Colombo, N.
    Gonzalez-Martin, A.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S738 - S739
  • [42] Clinical and molecular characteristics of patients with short- and long-term progression-free survival in the phase IIIb OPINION study of maintenance olaparib for patients with non-germline BRCA1/BRCA2-mutated platinum-sensitive relapsed ovarian cancer
    Lheureux, Stephanie
    Oaknin, Ana
    Sikorska, Magdalena
    Ledermann, Jonathan
    Blakeley, Chris
    Marshall, Helen
    Barnicle, Alan
    Poveda, Andres
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S160 - S160
  • [43] Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Moore, K. N.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Friedlander, M.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A. M.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E. S.
    Bloomfield, R.
    DiSilvestro, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 727 - 727
  • [44] Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
    Friedlander, M.
    Moore, K.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A. M.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E. S.
    Bloomfield, R.
    Disilvestro, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: Results from a randomized clinical trial
    Pokrzywinski, Robin
    Secord, Angeles Alvarez
    Havrilesky, Laura J.
    Puls, Larry E.
    Holloway, Robert W.
    Lewandowski, George S.
    Higgins, Robert V.
    Nycum, Lawrence R.
    Kohler, Matthew F.
    Revicki, Dennis A.
    GYNECOLOGIC ONCOLOGY, 2011, 123 (03) : 505 - 510
  • [46] Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial
    Thiery-Vuillemin, Antoine
    Saad, Fred
    Armstrong, Andrew J.
    Oya, Mototsugu
    Vianna, Karina
    Ozguroglu, Mustafa
    Gedye, Craig
    Buchschacher, Gary L.
    Lee, Ji Youl
    Emmenegger, Urban
    Navratil, Jiri
    Virizuela, Juan
    Salazar, Anibal
    Maillet, Denis
    Uemura, Hiroji
    Hosius, Christian
    De Champlain, Andre
    Barker, Laura
    Degboe, Arnold N.
    Clarke, Noel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice (TPC)
    Robson, M.
    Ruddy, K. J.
    Im, S-A.
    Senkus-Konefka, E.
    Xu, B.
    Domchek, S. M.
    Masuda, N.
    Delaloge, S.
    Li, W.
    Tung, N.
    Armstrong, A.
    Wu, W.
    Goessl, C.
    Degboe, A.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Health-Related Quality of Life (HRQoL)/Patient Reported Outcomes (PRO) of Patients (pts) With Partially Platinum Sensitive (PPS) Recurrent Ovarian Cancer (ROC) Treated in a Randomized Phase III Trial of Trabectedin and Pegylated Liposomal Doxorubicin (PLD) Vs PLD Alone (OVA-301) - an Exploratory Analysis
    Vergote, I.
    Bidzinski, M.
    Kelley, J.
    Vasanthan, S.
    Runnebaum, I.
    Vermorken, J.
    Arranz, J. A.
    Almorin, E.
    Park, Y.
    Lisyanskaya, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S536 - S536
12345